S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.13 (+0.56%)
AAPL   115.92 (+0.65%)
MSFT   213.90 (+0.02%)
FB   275.58 (-0.48%)
GOOGL   1,764.23 (+0.02%)
AMZN   3,180.70 (+2.01%)
TSLA   571.41 (+2.89%)
NVDA   529.46 (+2.15%)
BABA   276.39 (-1.28%)
CGC   26.94 (-0.11%)
GE   10.51 (+0.57%)
MU   63.58 (-0.58%)
AMD   86.95 (+2.21%)
T   28.91 (-1.09%)
NIO   52.99 (-0.97%)
F   9.03 (-4.44%)
ACB   8.82 (-4.44%)
NFLX   484.33 (+0.30%)
GILD   59.52 (-1.21%)
BA   218.07 (-0.19%)
DIS   148.75 (-1.81%)
S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.13 (+0.56%)
AAPL   115.92 (+0.65%)
MSFT   213.90 (+0.02%)
FB   275.58 (-0.48%)
GOOGL   1,764.23 (+0.02%)
AMZN   3,180.70 (+2.01%)
TSLA   571.41 (+2.89%)
NVDA   529.46 (+2.15%)
BABA   276.39 (-1.28%)
CGC   26.94 (-0.11%)
GE   10.51 (+0.57%)
MU   63.58 (-0.58%)
AMD   86.95 (+2.21%)
T   28.91 (-1.09%)
NIO   52.99 (-0.97%)
F   9.03 (-4.44%)
ACB   8.82 (-4.44%)
NFLX   484.33 (+0.30%)
GILD   59.52 (-1.21%)
BA   218.07 (-0.19%)
DIS   148.75 (-1.81%)
S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.13 (+0.56%)
AAPL   115.92 (+0.65%)
MSFT   213.90 (+0.02%)
FB   275.58 (-0.48%)
GOOGL   1,764.23 (+0.02%)
AMZN   3,180.70 (+2.01%)
TSLA   571.41 (+2.89%)
NVDA   529.46 (+2.15%)
BABA   276.39 (-1.28%)
CGC   26.94 (-0.11%)
GE   10.51 (+0.57%)
MU   63.58 (-0.58%)
AMD   86.95 (+2.21%)
T   28.91 (-1.09%)
NIO   52.99 (-0.97%)
F   9.03 (-4.44%)
ACB   8.82 (-4.44%)
NFLX   484.33 (+0.30%)
GILD   59.52 (-1.21%)
BA   218.07 (-0.19%)
DIS   148.75 (-1.81%)
S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.13 (+0.56%)
AAPL   115.92 (+0.65%)
MSFT   213.90 (+0.02%)
FB   275.58 (-0.48%)
GOOGL   1,764.23 (+0.02%)
AMZN   3,180.70 (+2.01%)
TSLA   571.41 (+2.89%)
NVDA   529.46 (+2.15%)
BABA   276.39 (-1.28%)
CGC   26.94 (-0.11%)
GE   10.51 (+0.57%)
MU   63.58 (-0.58%)
AMD   86.95 (+2.21%)
T   28.91 (-1.09%)
NIO   52.99 (-0.97%)
F   9.03 (-4.44%)
ACB   8.82 (-4.44%)
NFLX   484.33 (+0.30%)
GILD   59.52 (-1.21%)
BA   218.07 (-0.19%)
DIS   148.75 (-1.81%)
Log in
NYSE:BSX

Boston Scientific Stock Forecast, Price & News

$33.56
-0.23 (-0.68 %)
(As of 11/25/2020 02:51 PM ET)
Add
Compare
Today's Range
$33.50
Now: $33.56
$33.94
50-Day Range
$33.33
MA: $37.05
$41.97
52-Week Range
$24.10
Now: $33.56
$46.62
Volume267,966 shs
Average Volume10.76 million shs
Market Capitalization$48.06 billion
P/E Ratio12.86
Dividend YieldN/A
Beta0.98
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Read More
Boston Scientific logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.40 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP10113710
Phone508-683-4000
Employees36,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.74 billion
Cash Flow$2.39 per share
Book Value$10.87 per share

Profitability

Net Income$4.70 billion

Miscellaneous

Outstanding Shares1,431,921,000
Market Cap$48.06 billion
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$33.56
-0.23 (-0.68 %)
(As of 11/25/2020 02:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Boston Scientific (NYSE:BSX) Frequently Asked Questions

How has Boston Scientific's stock price been impacted by Coronavirus?

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BSX shares have decreased by 0.5% and is now trading at $33.68.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Boston Scientific?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 18 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Boston Scientific
.

What stocks does MarketBeat like better than Boston Scientific?

Wall Street analysts have given Boston Scientific a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Boston Scientific wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Boston Scientific
.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) posted its earnings results on Monday, November, 2nd. The medical equipment provider reported $0.37 EPS for the quarter, topping the consensus estimate of $0.25 by $0.12. Boston Scientific had a return on equity of 11.54% and a net margin of 36.59%.
View Boston Scientific's earnings history
.

What price target have analysts set for BSX?

24 equities research analysts have issued 12-month price targets for Boston Scientific's shares. Their forecasts range from $25.00 to $58.00. On average, they expect Boston Scientific's share price to reach $43.80 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price.
View analysts' price targets for Boston Scientific
.

Who are some of Boston Scientific's key competitors?

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), The Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and salesforce.com (CRM).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the following people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 55, Pay $3.57M)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 54, Pay $1.28M)
  • Mr. Edward F. Mackey, Exec. VP of Global Operations (Age 57, Pay $1.13M)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Interventional Cardiology (Age 56, Pay $1.24M)
  • Mr. Jonathan R. Monson, VP, Global Controller & Chief Accounting Officer

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by many different institutional and retail investors. Top institutional investors include Bollard Group LLC (2.24%), Nuveen Asset Management LLC (1.59%), Standard Life Aberdeen plc (0.69%), Newport Trust Co (0.61%), UBS Asset Management Americas Inc. (0.49%) and Charles Schwab Investment Management Inc. (0.45%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori.
View institutional ownership trends for Boston Scientific
.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, Epoch Investment Partners Inc., TD Asset Management Inc., Diamond Hill Capital Management Inc., Los Angeles Capital Management & Equity Research Inc., Cannell Peter B & Co. Inc., Bollard Group LLC, and Neuberger Berman Group LLC. Company insiders that have sold Boston Scientific company stock in the last year include Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, and Wendy Carruthers.
View insider buying and selling activity for Boston Scientific
.

Which major investors are buying Boston Scientific stock?

BSX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Winslow Capital Management LLC, Sei Investments Co., Caisse DE Depot ET Placement DU Quebec, Assenagon Asset Management S.A., Inverness Counsel LLC NY, Cubist Systematic Strategies LLC, and Jarislowsky Fraser Ltd.
View insider buying and selling activity for Boston Scientific
.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $33.68.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $48.23 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe.

What is Boston Scientific's official website?

The official website for Boston Scientific is www.bostonscientific.com.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.